A study designed to determine safety and efficacy of Daclizumab High Yield Process (DAC HYP) in patients with Multiple Sclerosis Who Have Completed Treatment in a previous study, 205MS202 (SELECTION)

Registry ID

EUCTR2009-015318-23

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Biogen Idec Ltd.

Start date

2010-01-21

Completion date

2016-08-30

Last update

2026-08-16

Conditions

• Relapsing-remitting Multiple Sclerosis

Summary

To assess the safety of extended treatment with DAC HYP monotherapy in subjects with RRMS.

Locations

• , , Hungary
• , , Czechia
• , , UK
• , , Germany

Related clinical trials

• RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
• Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
• A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis

View on source registry